KR920700288A - 펲티드 및 dna배열 - Google Patents

펲티드 및 dna배열

Info

Publication number
KR920700288A
KR920700288A KR1019900700595A KR900700595A KR920700288A KR 920700288 A KR920700288 A KR 920700288A KR 1019900700595 A KR1019900700595 A KR 1019900700595A KR 900700595 A KR900700595 A KR 900700595A KR 920700288 A KR920700288 A KR 920700288A
Authority
KR
South Korea
Prior art keywords
leu
ser
phe
acid sequence
polypeptide
Prior art date
Application number
KR1019900700595A
Other languages
English (en)
Other versions
KR100195632B1 (ko
Inventor
로버트 굳데이 앤드류우
폴 벨필드 그라함
슬립 다렐
Original Assignee
알란 에스 톰슨
델타 바이오테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817598A external-priority patent/GB8817598D0/en
Priority claimed from GB898906920A external-priority patent/GB8906920D0/en
Application filed by 알란 에스 톰슨, 델타 바이오테크놀로지 리미티드 filed Critical 알란 에스 톰슨
Publication of KR920700288A publication Critical patent/KR920700288A/ko
Application granted granted Critical
Publication of KR100195632B1 publication Critical patent/KR100195632B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Abstract

내용 없음

Description

펩티드 및 DNA배열
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 폴리스미드 pEK113의 제한효소지도이다,
제2도는 폴리스미드 pEK25의 제한효소지도이다,
제3도는 폴리스미드 pAYE230의 제한효소지도이다.

Claims (12)

  1. 하기와 같은 아미노산 배열:
    (a)H N－Met－Lys－Trp－Val－Ser－Phe－lle－Ser－Leu－Leu－Phe－Leu－Phe－Ser－Ser－Ala－Tyr－Ser－Arg－Ser－Leu－Asp－Lys－Arg－COOH 또는 (b)H N－Met－Asn－lle－Phe－tyr－lle－Phe－Leu－Phe－Leu－Leu－Ser－Phe－Val－Gln－Gly－Ser－Leu－Asp－Lys－Arg－COOH 또는 상기 어느 배열의 보전적 수식 변이형.
  2. 카르복실 말단에서 폴리펩티드의 N－말단 잔기에 연결된 제1항의 아미노산 배열을 포함하고 있는 융합체.
  3. 제2항에 있어서, 상기 아미노산 배열이 상기 폴립펩티드에 직접 연결되어 있는 융합체.
  4. 제3항에 있어서, 폴리펩티드가 자연발생 인체혈청 알부민, 수식된 인체형청 알부민 또는 상기 둘중 어느 것의 단편인 융합체.
  5. 제1항의 아미노산 배열 또는 제2항의 융합체에 대한 암호화 핵산배열.
  6. 제5항에 있어서, 표2 또는 표3에 제시된 배열로부터 선택된 핵산배열.
  7. 적절한 조절영역 또는 영역들 및, 조절영역의 조절하에 있는 제5항 또는 제6항의 핵산배열을 포함하는 DNA 구조.
  8. 제7항의 DNA구조로 형질전환된 숙주.
  9. 제8항의 사카로미세스 세레비지에(Saccharomyces cerevisiae) 또는 시조사카로미세스 폼베(Schizosaccharomyces pombe).
  10. 제8항 또는 제9항의 숙주를 배양하고 그들로부터 상기 핵산배열 또는 그 수식 변역체에 의하여 발현된 폴리펩티드를 얻는 것을 포함하는 폴리펩티드의 제조방법.
  11. 제10항의 방법으로 제조된 폴리펩티드.
  12. 제10항의 방법으로 제조된 인체혈청 알부빈 또는 그 변이형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019900700595A 1988-07-23 1989-07-14 펩티드 및 dna 배열 KR100195632B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB8817598.9 1988-07-23
GB888817598A GB8817598D0 (en) 1988-07-23 1988-07-23 Dna & peptide sequences
GB898906920A GB8906920D0 (en) 1989-03-28 1989-03-28 Peptide and dna sequences
GB896920.7 1989-03-28
GB8906920.7 1989-03-28
GBPGB89/00816 1989-07-14
PCT/GB1989/000816 WO1990001063A1 (en) 1988-07-23 1989-07-14 New secretory leader sequences

Publications (2)

Publication Number Publication Date
KR920700288A true KR920700288A (ko) 1992-02-19
KR100195632B1 KR100195632B1 (ko) 1999-06-15

Family

ID=26294196

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700595A KR100195632B1 (ko) 1988-07-23 1989-07-14 펩티드 및 dna 배열

Country Status (15)

Country Link
US (1) US5302697A (ko)
EP (1) EP0387319B1 (ko)
JP (1) JP3092811B2 (ko)
KR (1) KR100195632B1 (ko)
AT (1) ATE135045T1 (ko)
AU (1) AU633020B2 (ko)
CA (1) CA1340547C (ko)
DE (1) DE68925893T2 (ko)
DK (1) DK175853B1 (ko)
FI (1) FI104564B (ko)
GB (1) GB2230268B (ko)
HU (1) HU213571B (ko)
IE (1) IE62266B1 (ko)
IL (1) IL91024A (ko)
WO (1) WO1990001063A1 (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5759802A (en) * 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
EP0773296B1 (en) * 1995-02-03 2006-09-13 Asahi Glass Company Ltd. Secretory signal gene and expression vector having the same
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
EP1056474B1 (en) * 1997-11-07 2002-06-12 ConjuChem, Inc. Affinity markers for human serum albumin
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
JP2005538932A (ja) 2002-02-07 2005-12-22 アベンティス、ベーリング、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング アルブミン融合クニッツドメインペプチド
GB0217033D0 (en) * 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005055944A2 (en) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005317828A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
AU2007343796A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2008153745A2 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CN101835801B (zh) 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
DK2393834T3 (da) 2009-02-06 2013-06-24 Novozymes Biopharma Dk As Fremgangsmåde til oprensning
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
MX2011009797A (es) 2009-03-20 2012-01-12 Amgen Inc Inhibidores peptidicos de kv1.3 potentes selectivos.
MX2012005864A (es) 2009-11-20 2012-08-31 Amgen Inc Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
CN103314296A (zh) 2010-08-10 2013-09-18 安姆根有限公司 用于检测针对靶抗体的中和抗体的双功能体外靶结合测定
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
US20120185956A1 (en) 2011-01-18 2012-07-19 Gingras Jacinthe Global nav1.7 knockout mice and uses
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス，インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
AP2013007173A0 (en) 2011-03-16 2013-10-31 Amgen Inc Potent and selective inhibitors of NAV1.3 and NAV1.7
AU2013222188A1 (en) 2012-02-22 2014-09-11 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
EP3039129B1 (en) 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
US10202616B2 (en) 2014-10-15 2019-02-12 Amgen Inc. Promoter and regulatory elements for improved expression of heterologous genes in host cells
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3394243A1 (en) 2015-12-22 2018-10-31 Albumedix Ltd. Improved protein expression strains
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
CN111032871A (zh) 2017-06-20 2020-04-17 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
CN111344410B (zh) 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3924458A1 (en) 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2023287707A1 (en) 2021-07-15 2023-01-19 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
NZ207925A (en) * 1983-04-25 1988-05-30 Genentech Inc Yeast expression vehicle consisting of a yeast promoter and signal peptide encoding region linked to a heterologus peptide coding region; expression and culture
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
EP0206783A3 (en) * 1985-06-20 1988-10-05 The Salk Institute Biotechnology Industrial Associates, Inc. Expression and secretion of polypeptides from saccharomyces cerevisiae
RU2091490C1 (ru) * 1985-10-25 1997-09-27 Зимодженетикс, Инк. Способ получения гетерологичного полипептида в эукариотических микроорганизмов
WO1987002670A1 (en) * 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
GB8613388D0 (en) * 1986-06-03 1986-07-09 Delta Biotechnology Ltd Induction of galactose regulated gene expression in yeast
IT1196484B (it) * 1986-07-11 1988-11-16 Sclavo Spa Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
JP2507874B2 (ja) * 1986-11-27 1996-06-19 工業技術院長 分泌シグナルペプチドをコ−ドするｄｎａ配列

Also Published As

Publication number Publication date
DK175853B1 (da) 2005-04-04
HUT57829A (en) 1991-12-30
GB8928849D0 (en) 1990-07-18
EP0387319B1 (en) 1996-03-06
ATE135045T1 (de) 1996-03-15
DE68925893T2 (de) 1996-08-08
GB2230268A (en) 1990-10-17
KR100195632B1 (ko) 1999-06-15
FI901428A0 (fi) 1990-03-21
JP3092811B2 (ja) 2000-09-25
DK72990D0 (da) 1990-03-21
CA1340547C (en) 1999-05-18
HU213571B (en) 1997-08-28
WO1990001063A1 (en) 1990-02-08
IL91024A (en) 1995-08-31
EP0387319A1 (en) 1990-09-19
DK72990A (da) 1990-03-21
HU894572D0 (en) 1991-05-28
US5302697A (en) 1994-04-12
IE892361L (en) 1990-01-23
AU4042789A (en) 1990-02-19
JPH03500370A (ja) 1991-01-31
IL91024A0 (en) 1990-02-09
FI104564B (fi) 2000-02-29
DE68925893D1 (de) 1996-04-11
GB2230268B (en) 1992-01-29
IE62266B1 (en) 1995-01-11
AU633020B2 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
KR920700288A (ko) 펲티드 및 dna배열
KR987000085A (ko) 헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides)
DK105489D0 (da) Polypeptid
JP3730256B2 (ja) 分泌シグナル遺伝子およびそれを有する発現ベクター
EP0509553A1 (en) Anti-lymphotoxin antibody, its production and use
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
DE3584260D1 (de) Die synthese eines proteins mittels eines identifizierungspeptids.
KR890010199A (ko) 활성화된 사람의 단백질 c의 직접 발현용 벡터 및 화합물
ATE63757T1 (de) Expression durch verwendung von fusionsgenen fuer proteinproduktion.
ATE265538T1 (de) Verfahren zur sekretion thrombopoitin polypeptide
KR927003812A (ko) 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조
KR970065558A (ko) 분비형 Kex2 유도체의 제조방법
DE69030937T2 (de) Mutanten von Interleukin-3
US5206153A (en) Method of producing human α-fetoprotein and product produced thereby
ATE317443T1 (de) N-terminal verlängerte proteine exprimiert in hefe
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
Tanaka et al. The amino acid sequence of two small ribosomal proteins from Bacillus stearothermophilus
EP0750040A3 (en) Macrophage stimulating protein variant and method for producing the same
JPS6443193A (en) Production of phospholipase a2
RU97115447A (ru) Химерные белки gnrh и лейкотоксина

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120203

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee